Skip to main content
Clinical Trials/NCT04398511
NCT04398511
Completed
Phase 2

The Effect of Lactobacillus Brevis CD2 on Traumatic Oral Lesions Induced by Fixed Orthodontic Appliance: a Randomized Clinical Trial

Universidade de Passo Fundo1 site in 1 country20 target enrollmentStarted: January 7, 2019Last updated:

Overview

Phase
Phase 2
Status
Completed
Sponsor
Universidade de Passo Fundo
Enrollment
20
Locations
1
Primary Endpoint
Number of days without traumatic oral lesions

Overview

Brief Summary

Introduction: Traumatic oral lesions are common in the beginning of the orthodontic treatment, and pathogenic oral bacteria might be involved. We tested whether the probiotic Lactobacillus brevis CD2 (L brevis) is benefic in this condition. Methods: In a double-blind clinical trial, 20 patients were randomized to 21 days course of lozenges containing L brevis CD2 (4 billion colony-forming units after breakfast, lunch and dinner) or placebo, starting on the day of installation of the fixed orthodontic appliance. Main outcomes were days without oral lesions and oral pain score [ranging between 0 (no pain) and 10 (maximum)]. Oral health related quality of life was measured by OHIP-14 before and after treatments.

Detailed Description

Study protocol After signing the informed consent form, the patients underwent an oral examination and answered about clinical information, oral pain scale, and the OHIP-14 questionnaire. The pain scale was graded between 0 (no pain) and 10 (maximum), Likert standard. There was also a drawing for the distribution of coded treatments, through a number taken by the patient from a manila envelope. After the orthodontic appliance installation session, each patient was instructed to use the coded treatment for the next 21 days, two gums after breakfast, after lunch and after dinner, totalizing 12 billion UFC of L brevis or placebo per day. The patient was provided with a diary to note the daily appearance of lesions and their evolution during the 21-day period, as well as the occurrence of any new symptoms (potential adverse effect), in addition to proof of the commitment assumed by the use of the tablets. After 21 days, each patient was reexamined by the author of the study, who collected the diaries and obtained information regarding the oral examination, oral pain scale, data on adherence to treatment and self-completion of the OHIP-14.

Statistical analysis Quantitative data are described with mean and standard deviation (or standard error of the mean) or median and range, while qualitative data are displayed with absolute and relative frequencies. Student's t-test was used for comparison of quantitative data between groups, Wilcoxon-Mann-Whitney (WMW) test being employed when the assumptions for that test were not met. Exact chi-square and Fisher´s exact test (FET) were used for categorical data. Treatment effect on OHIP-14 was analyzed using a Generalize Estimating Equations (GEE) model with Poisson distribution and log link, the predictors being treatment, time (beginning and end of treatment) and interaction treatment*time. The analyses were performed with softwares GraphPrism version 4.0 and SPSS® (IBM SPSS statistics v18). Sample size was estimated using WinPEPI v11.65. The P value indicative of significance was < 0.05. Because the final outcome was prevention or mitigation (not maintenance or augmentation) of undesirable symptoms, one-tailed tests were used for comparisons between groups respect to days without oral lesions, oral pain and OHIP-14 scores.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Triple (Participant, Care Provider, Outcomes Assessor)

Masking Description

Patients were treated with identical lozenges containing probiotic or placebo. The treatments were revealed only after statistical analysis.

Eligibility Criteria

Ages
14 Years to 60 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • need for orthodontic treatment with fixed appliance

Exclusion Criteria

  • Oral lesions
  • Uncompensated systemic diseases
  • Regular use of corticoids, antibiotics, immuno regulators and antidepressive agents

Arms & Interventions

L brevis

Experimental

Lactobacillus brevis CD2 in lozenges containing 4 billion CFU. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.

Intervention: L brevis (Drug)

Placebo

Placebo Comparator

Placebo in lozenges, identical to those of L brevis. Patients used a lozenge 15 min after breakfast, lunch and dinner, during 21 days, starting in the day of installation of the orthodontic appliance.

Intervention: Placebo (Drug)

Outcomes

Primary Outcomes

Number of days without traumatic oral lesions

Time Frame: First 21 days after appliance installation

Oral lesions (ulcers) due to fixed orthodontic appliance

Oral pain scale

Time Frame: First 21 days after appliance installation

Oral pain score measured by Likert scale between 0 (no pain) and 10 (maximum pain)

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Universidade de Passo Fundo
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Fernando Fornari

Professor

Universidade de Passo Fundo

Study Sites (1)

Loading locations...

Similar Trials